Published in Women's Health Weekly, April 19th, 2001
R.A. Cohen and colleagues at Brown University, Rhode Island, evaluated the neurocognitive function of severely immune-impaired HIV+ women treated with HAART compared with untreated women.
They found that women treated with a HAART regimen had significantly enhanced neurocognitive function compared with their untreated counterparts, and that functional improvements increased with the length of HAART treatment.
For women with immune CD4 cell counts reduced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.